APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Phosphoinositide 3-Kinase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Phosphoinositide 3-Kinase Inhibitor Market Analysis and Forecast 2026-2032

Report ID 174025540230 December 2025197 pages

Choose your research edition.

Industry ResearchPhosphoinositide 3-Kinase Inhibitor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphoinositide 3-Kinase Inhibitor Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Phosphoinositide 3-Kinase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphoinositide 3-Kinase Inhibitor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphoinositide 3-Kinase Inhibitor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Phosphoinositide 3-Kinase Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Phosphoinositide 3-Kinase Inhibitor include Gilead Sciences Inc., Secura Bio, Inc., TG Therapeutics Inc., Bayer AG and Novartis AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Phosphoinositide 3-Kinase Inhibitor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Phosphoinositide 3-Kinase Inhibitor, also provides the revenue of main regions and countries. Of the upcoming market potential for Phosphoinositide 3-Kinase Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Phosphoinositide 3-Kinase Inhibitor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Phosphoinositide 3-Kinase Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Phosphoinositide 3-Kinase Inhibitor revenue, projected growth trends, production technology, application and end-user industry.

Phosphoinositide 3-Kinase Inhibitor Segment by Company

Gilead Sciences Inc.

Secura Bio, Inc.

TG Therapeutics Inc.

Bayer AG

Novartis AG

Phosphoinositide 3-Kinase Inhibitor Segment by Type

Dual PI3K/mTOR inhibitors

Pan-PI3K Inhibitors

Other

Phosphoinositide 3-Kinase Inhibitor Segment by Application

FL - Follicular Iymphoma

CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma

Other Indications

Phosphoinositide 3-Kinase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphoinositide 3-Kinase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphoinositide 3-Kinase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphoinositide 3-Kinase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Phosphoinositide 3-Kinase Inhibitor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Phosphoinositide 3-Kinase Inhibitor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phosphoinositide 3-Kinase Inhibitor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Phosphoinositide 3-Kinase Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Dual PI3K/mTOR inhibitors Major Player Table 3. Pan-PI3K Inhibitors Major Player Table 4. Other Major Player Table 5. Global Phosphoinositide 3-Kinase Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. FL - Follicular Iymphoma Major Player Table 7. CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma Major Player Table 8. Other Indications Major Player Table 9. Phosphoinositide 3-Kinase Inhibitor Industry Trends Table 10. Phosphoinositide 3-Kinase Inhibitor Industry Drivers Table 11. Phosphoinositide 3-Kinase Inhibitor Industry Opportunities and Challenges Table 12. Phosphoinositide 3-Kinase Inhibitor Industry Restraints Table 13. Global Phosphoinositide 3-Kinase Inhibitor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Phosphoinositide 3-Kinase Inhibitor Market Share by Region (2021-2026) Table 16. Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Phosphoinositide 3-Kinase Inhibitor Market Share by Region (2027-2032) Table 18. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Players (2021-2026) Table 20. Global Phosphoinositide 3-Kinase Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Phosphoinositide 3-Kinase Inhibitor Key Players Headquarters & Area Served Table 22. Global Phosphoinositide 3-Kinase Inhibitor Players, Product Type & Application Table 23. Global Phosphoinositide 3-Kinase Inhibitor Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Phosphoinositide 3-Kinase Inhibitor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Type (2021-2026) Table 30. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Type (2027-2032) Table 31. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2021-2026) Table 35. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2027-2032) Table 36. Gilead Sciences Inc. Company Information Table 37. Gilead Sciences Inc. Business Overview Table 38. Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 40. Gilead Sciences Inc. Recent Development Table 41. Secura Bio, Inc. Company Information Table 42. Secura Bio, Inc. Business Overview Table 43. Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 45. Secura Bio, Inc. Recent Development Table 46. TG Therapeutics Inc. Company Information Table 47. TG Therapeutics Inc. Business Overview Table 48. TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 50. TG Therapeutics Inc. Recent Development Table 51. Bayer AG Company Information Table 52. Bayer AG Business Overview Table 53. Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 55. Bayer AG Recent Development Table 56. Novartis AG Company Information Table 57. Novartis AG Business Overview Table 58. Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio Table 60. Novartis AG Recent Development Table 61. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 75. China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 76. China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 77. China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 78. China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Phosphoinositide 3-Kinase Inhibitor Image Figure 2. Global Phosphoinositide 3-Kinase Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphoinositide 3-Kinase Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Dual PI3K/mTOR inhibitors Image Figure 5. Pan-PI3K Inhibitors Image Figure 6. Other Image Figure 7. Global Phosphoinositide 3-Kinase Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Phosphoinositide 3-Kinase Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 9. FL - Follicular Iymphoma Image Figure 10. CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma Image Figure 11. Other Indications Image Figure 12. Global Phosphoinositide 3-Kinase Inhibitor Market Size (US$ Million) & (2021-2032) Figure 13. Global Phosphoinositide 3-Kinase Inhibitor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Phosphoinositide 3-Kinase Inhibitor Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Phosphoinositide 3-Kinase Inhibitor Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Type (2021-2032) Figure 20. Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2021-2032) Figure 23. North America Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032) Figure 25. North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032) Figure 26. North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Country (2021-2032) Figure 27. United States Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032) Figure 32. Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032) Figure 33. Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Country (2021-2032) Figure 34. Germany Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032) Figure 44. China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032) Figure 45. Asia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032) Figure 47. Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032) Figure 48. Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Region (2021-2032) Figure 49. Japan Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032) Figure 57. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032) Figure 58. SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Country (2021-2032) Figure 59. Brazil Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Phosphoinositide 3-Kinase Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Dual PI3K/mTOR inhibitors
  • Pan-PI3K Inhibitors
  • Other
Applications
  • FL - Follicular Iymphoma
  • CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
  • Other Indications
Companies covered
  • Gilead Sciences Inc.
  • Secura Bio, Inc.
  • TG Therapeutics Inc.
  • Bayer AG
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Phosphoinositide 3-Kinase Inhibitor Market by Type
  3. 1.2.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Dual PI3K/mTOR inhibitors
  5. 1.2.3 Pan-PI3K Inhibitors
  6. 1.2.4 Other
  7. 1.3 Phosphoinositide 3-Kinase Inhibitor Market by Application
  8. 1.3.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 FL - Follicular Iymphoma
  10. 1.3.3 CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
  11. 1.3.4 Other Indications
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Phosphoinositide 3-Kinase Inhibitor Market Dynamics
  1. 2.1 Phosphoinositide 3-Kinase Inhibitor Industry Trends
  2. 2.2 Phosphoinositide 3-Kinase Inhibitor Industry Drivers
  3. 2.3 Phosphoinositide 3-Kinase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Phosphoinositide 3-Kinase Inhibitor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Phosphoinositide 3-Kinase Inhibitor Market Perspective (2021-2032)
  2. 3.2 Global Phosphoinositide 3-Kinase Inhibitor Growth Trends by Region
  3. 3.2.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2021-2026)
  5. 3.2.3 Global Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players
  2. 4.1.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players (2021-2026)
  3. 4.1.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Phosphoinositide 3-Kinase Inhibitor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Phosphoinositide 3-Kinase Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Phosphoinositide 3-Kinase Inhibitor Key Players Headquarters & Area Served
  7. 4.4 Global Phosphoinositide 3-Kinase Inhibitor Players, Product Type & Application
  8. 4.5 Global Phosphoinositide 3-Kinase Inhibitor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Phosphoinositide 3-Kinase Inhibitor Market CR5 and HHI
  11. 4.6.3 2025 Phosphoinositide 3-Kinase Inhibitor Tier 1, Tier 2, and Tier 3
5 Phosphoinositide 3-Kinase Inhibitor Market Size by Type
  1. 5.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 5.3 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Type (2021-2032)
6 Phosphoinositide 3-Kinase Inhibitor Market Size by Application
  1. 6.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  3. 6.3 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Gilead Sciences Inc.
  2. 7.1.1 Gilead Sciences Inc. Company Information
  3. 7.1.2 Gilead Sciences Inc. Business Overview
  4. 7.1.3 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  6. 7.1.5 Gilead Sciences Inc. Recent Developments
  7. 7.2 Secura Bio, Inc.
  8. 7.2.1 Secura Bio, Inc. Company Information
  9. 7.2.2 Secura Bio, Inc. Business Overview
  10. 7.2.3 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  12. 7.2.5 Secura Bio, Inc. Recent Developments
  13. 7.3 TG Therapeutics Inc.
  14. 7.3.1 TG Therapeutics Inc. Company Information
  15. 7.3.2 TG Therapeutics Inc. Business Overview
  16. 7.3.3 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  18. 7.3.5 TG Therapeutics Inc. Recent Developments
  19. 7.4 Bayer AG
  20. 7.4.1 Bayer AG Company Information
  21. 7.4.2 Bayer AG Business Overview
  22. 7.4.3 Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  24. 7.4.5 Bayer AG Recent Developments
  25. 7.5 Novartis AG
  26. 7.5.1 Novartis AG Company Information
  27. 7.5.2 Novartis AG Business Overview
  28. 7.5.3 Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Portfolio
  30. 7.5.5 Novartis AG Recent Developments
8 North America
  1. 8.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue (2021-2032)
  2. 8.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 8.2.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026)
  4. 8.2.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032)
  5. 8.3 North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032)
  6. 8.4 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  7. 8.4.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026)
  8. 8.4.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032)
  9. 8.5 North America Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032)
  10. 8.6 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country
  11. 8.6.1 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026)
  13. 8.6.3 North America Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue (2021-2032)
  2. 9.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032)
  5. 9.3 Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032)
  9. 9.5 Europe Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country
  11. 9.6.1 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Phosphoinositide 3-Kinase Inhibitor Revenue (2021-2032)
  2. 10.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 10.2.1 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026)
  4. 10.2.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032)
  5. 10.3 China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032)
  6. 10.4 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  7. 10.4.1 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026)
  8. 10.4.2 China Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032)
  9. 10.5 China Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue (2021-2032)
  2. 11.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032)
  5. 11.3 Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032)
  9. 11.5 Asia Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country
  11. 11.6.1 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue (2021-2032)
  2. 12.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country
  11. 12.6.1 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Phosphoinositide 3-Kinase Inhibitor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst